Freedom to research in Australia - exemptions to patent infringement
We consider patent infringement exemptions of particular relevance to the life sciences.
We consider patent infringement exemptions of particular relevance to the life sciences.
We review the new stockholding and discounting requirements introduced by the Strategic Agreements with the Australian Government.
This article is part one in a series where we summarise the key amendments and the relevant commencement dates.
The TGA recently released its Guidance for ASX announcements addressing the need to comply with both therapeutic goods advertising requirements and continuous disclosure obligations
We analyse the recent high profile withdrawal of an application to the ACCC for authorisation of a patent litigation settlement by Juno and Celgene.
A reference committee has been appointed to conduct a review of the Health Technology Assessment policy and methods.
We consider the Patent Office’s decision in Sanofi v Amgen and the future for functional antibody claims under the ‘Raising the Bar’ regime.
We summarise guidance from recent tribunal decisions on the use of restrictive practices in residential aged care services.
We provide an update on changes to legislation regarding informed consent.
We assess the Federal Court’s approach to indemnity costs in recent patent cases.